Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a research note on Tuesday, December 10th.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $0.25 on Monday. The stock’s 50 day moving average price is $0.29 and its 200 day moving average price is $0.46. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.68.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.